Cargando…
Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors
BACKGROUND: Lipids A, the lipophilic partial structure of lipopolysaccharides, induce regression of several tumor types in animal models. Rather than exerting direct cytotoxic effect, these compounds trigger the immune system which in turn stimulates secretion of cytokines, and activates the inducib...
Autores principales: | Isambert, Nicolas, Fumoleau, Pierre, Paul, Catherine, Ferrand, Christophe, Zanetta, Sylvie, Bauer, Jacques, Ragot, Kevin, Lizard, Gérard, Jeannin, Jean-François, Bardou, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626800/ https://www.ncbi.nlm.nih.gov/pubmed/23547558 http://dx.doi.org/10.1186/1471-2407-13-172 |
Ejemplares similares
-
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012) -
Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours
por: Fumoleau, Pierre, et al.
Publicado: (2013) -
Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study
por: Isambert, Nicolas, et al.
Publicado: (2018) -
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
por: Fumet, Jean-David, et al.
Publicado: (2018) -
Hall 174
por: Jacob, U
Publicado: (1977)